Pemvidutide cuts heavy drinking days in Phase 2 alcohol use disorder trial
Pemvidutide reduced heavy drinking days in Altimmune’s Phase 2 RECLAIM trial, but gastrointestinal side effects and limited patient diversity remain.
Pharma & Biotech